Dermatitis News

If there is anything to know about dry skin as summertime sets in, it is that “it can still happen,” according to Stephen R. Humphrey, MD, Society for Pediatric Dermatology external marketing committee chair.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion of Adtralza for injection in a new single-dose 2 ml pre-filled pen, according to a press release.

Molecular changes in barrier function and inflammatory markers characterized the pathophysiology of atopic dermatitis at age 1 month, according to a study published in the Journal of the European Academy of Dermatology and Venereology.

Compared with the systemic calcineurin inhibitor standard cyclosporine, tacrolimus shows promise for numerous dermatologic conditions, whereas the literature on voclosporin is limited, according to a study.

An increased rate of venous thromboembolism is associated with atopic dermatitis in adults, although that increased risk is small, according to a study.

The quality and quantity of ultraviolet B phototherapy sessions for the treatment of atopic dermatitis did not increase the risk of skin cancer development in patients, according to a study.

Patients with moderate to severe atopic dermatitis that switched from dupilumab to upadacitinib experienced significant improvement in efficacy and itch as early as week 4 of treatment, according to a study.

Mindfulness and self-compassion training may be an effective treatment option to increase the quality of life for adults with atopic dermatitis, according to data published in JAMA Dermatology.

The pipeline of Janus kinase inhibitors is robust even as researchers struggle to fully understand how they work, according to a presenter at the 2023 Biologic Therapies Summit.

The second of two phase 3 studies evaluating Vtama cream 1% in adults and children aged as young as 2 years with atopic dermatitis showed consistent safety and efficacy results, Dermavant Sciences announced in a press release.